Yubo International Biotech Limited (YBGJ)

YBGJ Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0	0.6	0.1	1.24	1.35
Revenue Growth (YoY)	-99.43%	479.84%	-91.62%	-8.09%	-
Cost of Revenue	0.21	0.19	0.05	0.42	0.11
Gross Profit	-0.21	0.42	0.05	0.82	1.24
Selling, General & Admin	1.25	1.11	1.05	1.49	1.2
Other Operating Expenses	0.34	0.32	0.23	0.8	0.74
Operating Expenses	1.77	1.61	1.26	2.36	1.95
Operating Income	-1.98	-1.19	-1.21	-1.54	-0.71
Interest Expense	-	-0	-	-	-0
Interest & Investment Income	0	-	0	0	-
Pretax Income	-1.98	-1.2	-1.2	-1.54	-0.71
Earnings From Continuing Operations	-1.98	-1.2	-1.2	-1.54	-0.71
Minority Interest in Earnings	0.21	-	-	-	-
Net Income	-1.78	-1.2	-1.2	-1.54	-0.71
Net Income to Common	-1.78	-1.2	-1.2	-1.54	-0.71
Shares Outstanding (Basic)	120	12	119	118	116
Shares Outstanding (Diluted)	120	12	119	118	116
Shares Change (YoY)	900.00%	-89.91%	0.50%	1.94%	1058.84%
EPS (Basic)	-0.01	-0.10	-0.01	-0.01	-0.01
EPS (Diluted)	-0.01	-0.10	-0.01	-0.01	-0.01
Free Cash Flow	-1.34	-0.74	-0.6	-1.59	0.06
Free Cash Flow Per Share	-0.01	-0.06	-0.01	-0.01	0.00
Gross Margin	-	69.32%	50.49%	65.95%	91.56%
Operating Margin	-57113.60%	-197.58%	-1155.72%	-123.99%	-52.58%
Profit Margin	-51161.47%	-197.64%	-1155.50%	-123.95%	-52.58%
Free Cash Flow Margin	-38551.27%	-122.21%	-576.27%	-127.42%	4.32%
EBITDA	-1.8	-1	-1.18	-1.52	-0.7
EBITDA Margin	-	-166.15%	-	-122.27%	-51.61%
D&A For EBITDA	0.18	0.19	0.03	0.02	0.01
EBIT	-1.98	-1.19	-1.21	-1.54	-0.71
EBIT Margin	-	-197.58%	-	-123.99%	-52.58%

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.